conjugated pneumococcal vaccine
Phase 3Vaccine
conjugated pneumococcal vaccine is one of 11 biologic programs targeting Ataxia-telangiectasia. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Ataxia-Telangiectasia
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Glucophage
EMD SeronoApproved
Amantadine Sulphate
SSheba Medical Center
Approved
Lioresal
NovartisPhase 1
N-Acetyl-L-Leucine
IIntraBio Inc
Phase 3
IB1001
MMedexus Pharma, Inc.
Phase 2
conjugated pneumococcal vaccine
IInstitute of Child Health
Phase 3
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Prevenar
GSKPreclinical
Nicotinamide Riboside
UUniversity of Oklahoma
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunization1 trial
Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization
Completed·—··NCT02712177·4,535 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 3[1]
- Company
- IInstitute of Child Health